Clinical Trials Logo

Premature Coronary Heart Disease clinical trials

View clinical trials related to Premature Coronary Heart Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06164730 Not yet recruiting - Clinical trials for Heterozygous Familial Hypercholesterolemia

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Start date: May 2024
Phase: Phase 1
Study type: Interventional

VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.